Johnson & Johnson (J&J) is an American multinational, pharmaceutical, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company’s current chairman and chief executive officer, Joaquin Duato.
Johnson & Johnson was founded in 1886, by three brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson selling ready-to-use sterile surgical dressings. In 2023, the company split off its consumer healthcare business sector into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.
As part of our company’s evolution, we are updating our branding and uniting our Innovative Medicine and MedTech businesses under the Johnson & Johnson name to demonstrate our collective power in healthcare. Our refreshed identity reflects boldness that conveys our ability to tackle the world’s toughest health challenges, while staying true to our heritage of care and humanity.
We are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care … and profoundly impact health for humanity.
Johnson & Johnson Innovative Medicine
Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow.
Our diverse portfolio spans multiple therapeutic areas—Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina.
We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.
